Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q1 2017 · 10-Q
Revenue$0.00$0.00no prior Q1 2016 on file Net Income-$1.97M-$1.97MN/M vs Q1 2016 EPS Diluted-$0.51-$0.51N/M vs Q1 2016 Operating Income-$1,963,300N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
ended Jun 30, 2016 · filed Aug 12, 2016 · 43 d after period end